Monitor for next earnings release or clinical trial updates — this activity appears to be routine option monetization rather than a signal of distress. However, absence of buying and concentration of selling among top executives warrants caution if repeated in future periods.
Price Chart
Executive Summary
Multiple C-suite executives at Bicara Therapeutics (BCAX) exercised stock options and sold shares in the open market over a 7-day period, generating over $483,000 in total proceeds from sales. The transactions were primarily driven by option exercises followed by corresponding sales to cover taxes and realize gains, with no open-market purchases observed.
Key Financial Metrics
Key Facts
- CEO Mazumdar Claire and CFO Hyep Ivan exercised derivative securities (stock options) and sold the resulting shares in open-market transactions.
- Total open-market sales amounted to $483,168.03 across 30,200 shares sold at prices between $18.52 and $18.95.
- All transactions involving cash proceeds were sales; no open-market purchases were made.
- Non-cash transactions (codes M and A) totaled $81,611.52 in value, related to option exercises at $3.7898 strike price.
- Total insider selling represents approximately 0.048% of the company's $1.0B market cap — below the 0.1% threshold for materiality.
Financial Impact
$483,168 in open-market insider selling over 7 days, plus $81,612 in non-cash option exercises
Risk Factors
- Perception of lack of confidence if insiders continue to sell without reinvesting
- Potential for negative sentiment if no offsetting positive catalysts emerge soon
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (12 trades, 7d window) | cluster-BCAX-1774395923664 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | 8-K | $24.73 $19.78 | ▼ −20.02% | ▼ −20.24% | $18.25 (−26.18%) |
Aug 14, 2026 7w ago | Press Release | $24.28 $23.20 | ▼ −4.45% | ▼ −2.46% | $18.25 (−24.81%) |
Aug 12, 2026 7w ago | Insider Cluster | $23.63 $22.81 | ▼ −3.47% | ▼ −1.72% | $18.25 (−22.75%) |
Aug 12, 2026 7w ago | Insider Cluster | $23.63 $22.81 | ▼ −3.47% | ▼ −1.72% | $18.25 (−22.75%) |
Aug 11, 2026 7w ago | 8-K | $23.76 $23.64 | ▼ −0.51% | ▲ +0.55% | $18.25 (−23.17%) |
Aug 11, 2026 7w ago | Press Release | $23.76 $23.64 | ▼ −0.51% | ▲ +0.55% | $18.25 (−23.17%) |
Jul 14, 2026 11w ago | Insider Cluster | $28.10 $23.76 | ▼ −15.44% | ▼ −17.94% | $18.25 (−35.04%) |
Jun 11, 2026 16w ago | Institutional Cluster | $21.28 $29.68 | ▼ −39.47% | ▼ −37.58% | $18.25 (+14.22%) |
May 26, 2026 18w ago | Insider Cluster | $21.58 $26.34 | ▲ +22.06% | ▲ +23.96% | $18.25 (−15.41%) |
May 11, 2026 20w ago | 8-K | $22.92 $20.56 | ▼ −10.30% | ▼ −9.99% | $18.25 (−20.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access